E-submission
Search
- Page Path
- HOME > Search
Newsletter
- What's new in molecular genetic pathology 2026: emerging biomarkers for personalized cancer therapies
- Umberto Maccio
- Received November 24, 2025 Accepted January 3, 2026 Published online January 3, 2026
- DOI: https://doi.org/10.4132/jptm.2026.01.03 [Epub ahead of print]
- 63 View
- 10 Download
-
Abstract
PDF - New and emerging biomarkers and current molecular assays for the most prevalent and lethal cancers worldwide—breast, lung, prostate, and colorectal cancer—are described. Notably, HER2-low breast cancer and HER2-mutated non-small cell lung cancer have recently been recognized as targetable entities. In addition, various tissue-based analyses are now available to assess prognosis and the risk of relapse in prostate cancer.
First
Prev
